Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06880549 | A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 42 | — | — | Mar 25, 2025 | Aug 3, 2027 | May 27, 2026 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| Arm 1 (Dose Escalation): mRNA-4106 Alone | EXPERIMENTAL | Participants will receive mRNA-4106 at a test dose as monotherapy. |
| Arm 2 (Dose Escalation): mRNA-4200 Alone and in Combination with Pembrolizumab | EXPERIMENTAL | Participants will receive mRNA-4200 as monotherapy, followed by mRNA-4200 in combination with pembrolizumab, and continuation of pembrolizumab alone. |
| Name | Type | Description |
|---|---|---|
| mRNA-4106 | BIOLOGICAL | Intramuscular injection |
| Pembrolizumab | BIOLOGICAL | Intravenous infusion |
| mRNA-4200 | BIOLOGICAL | Intramuscular injection |
Key Inclusion Criteria: * Arm 1: Histologically confirmed advanced or metastatic cancer (melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), esophageal carcinoma, head and neck squamous cell carcinoma (HNSCC), urinary bladder cancer (UBC), colon/rectal adenocarcinomas, gas...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |